IM23 / Beijing Imunopharm - LARVOL DELTA

Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T) (clinicaltrials.gov) - P1 | N=10 | Completed | Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd. | Unknown status ➔ Completed | N=15 ➔ 10

CAR T-Cell Therapy • Enrollment change • Trial completion • Acute Myelogenous Leukemia